Xiang, W., Lam, Y. H., Periyasamy, G., & Chuah, C. (2022). Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress. International Journal of Molecular Sciences, 23(5), 2863. https://doi.org/10.3390/ijms23052863
Abstract:
Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by extensive heterogeneity in genetics, response to therapy and long-term outcomes, making it a prototype example of development for personalized medicine. Given the accessibility to hematologic malignancy patient samples and recent advances in high-throughput technologies, large amounts of biological data that are clinically relevant for diagnosis, risk stratification and targeted drug development have been generated. Recent studies highlight the potential of implementing genomic-based and phenotypic-based screens in clinics to improve survival in patients with refractory AML. In this review, we will discuss successful applications as well as challenges of most up-to-date high-throughput technologies, including artificial intelligence (AI) approaches, in the development of personalized medicine for AML, and recent clinical studies for evaluating the utility of integrating genomics-guided and drug sensitivity testing-guided treatment approaches for AML patients.
License type:
Attribution 4.0 International (CC BY 4.0)
Funding Info:
This research is supported by core funding from: Experimental Drug Development Centre
Grant Reference no. : NRF2021-IE-IECF-001
This research / project is supported by the National Medical Research Council - Centre Grant Programme
Grant Reference no. : NMRC/CG/C012A/2017